Most Recent Articles by Diana Ernst, RPh
The FDA has approved lacosamide for treating pediatric patients with partial-onset seizures.
The FDA has granted Fast Track status to an investigational agent for the treatment of Alzheimer disease.
Patients experienced reduced disease activity when switched to alemtuzumab.
There are no FDA-approved MS therapies for the pediatric population.
There is a higher risk for opioid-related death in patients taking concomitant prescription opioids and gabapentin.
More Articles by Diana Ernst, RPh
Neurology Advisor Articles
- Coffee Consumption May Decrease Stroke Risk
- Stroke Risk Predicted by Dietary Sodium:Potassium Ratio
- Patent Foramen Ovale and Migraine: Is It Time to Close the Book?
- Publication Bias in Neurology Research: Why It Matters and Why It Needs to Change
- Neuropsychiatric Conditions Common in Relatives of Patients With Amyotrophic Lateral Sclerosis
- Treating Cluster Headache: Weighing Current Therapies
- Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly
- Better Migraine Pain Relief With IV Non-Opioid Combination vs IV Hydromorphone
- FDA Approves Myasthenia Gravis Treatment
- Brain Inflammation Associated With Depression, Anxiety in Multiple Sclerosis
- CTE Confirmed With Antemortem PET Imaging, Autopsy in Professional Football Player
- Childhood Abuse Associated With Migraine, Neuroticism in Adulthood
- Patients With Parkinson Disease Are at High Risk for Depression
- Improving Outcomes of Peripheral Nerve Surgery
- Thrombectomy Recommended in Stroke Patients With Mismatched Deficit, Infarct Volume